Opendata, web and dolomites

HAP2 SIGNED

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 HAP2 project word cloud

Explore the words cloud of the HAP2 project. It provides you a very rough idea of what is the project "HAP2" about.

12    complete    therapies    placed    drug    urgently    defective    outcome    precision    incidence    stratified    prevention    fight    gamma    preventive    ifn    recommendations    clinical    hospital    ground    500    despite    antibiotic    bacterial    hap    severe    supplementation    expertise    academia    resistance    pneumonia    host    infections    social    interactions    risk    trials    omics    respiratory    infection    frequent    biomarkers    consumption    critical    acquired    immunosuppression    integrative    clinico    diseases    reappraisal    capitalising    patients    hap2    alternative    illness    predict    medicine    dysbiosis    resistant    infectious    drugs    variation    survival    breaking    immunology    microbiome    directed    axis    episodes    30    score    interdisciplinary    ambition    industry    dramatic    altering    pathogens    il    hospitals    pathogen    uniquely    treatment    first    cure    biological    world    disease    medical    course    strategies    sciences    genetic    physiopathology    revolutionize   

Project "HAP2" data sheet

The following table provides information about the project.

Coordinator
CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES 

Organization address
address: Allee de l'Ile Gloriette 5
city: NANTES
postcode: 44093
website: www.chu-nantes.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 9˙996˙350 €
 EC max contribution 9˙996˙350 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Two-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2024-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES FR (NANTES) coordinator 3˙642˙770.00
2    UNIVERSITAT ZURICH CH (ZURICH) participant 1˙510˙587.00
3    UNIVERSITE DE NANTES FR (NANTES CEDEX 1) participant 1˙273˙025.00
4    FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA ES (BARCELONA) participant 841˙365.00
5    STICHTING KATHOLIEKE UNIVERSITEIT NL (NIJMEGEN) participant 785˙000.00
6    NEUMEDICINES INC. US (TUJUNGA CA) participant 732˙127.00
7    BIG DATA SANTE FR (NANTES) participant 477˙328.00
8    UNIVERSITY OF MICHIGAN THE REGENTS OF THE UNIVERSITY OF MICHIGAN US (ANN ARBOR) participant 322˙837.00
9    HOSPICES CIVILS DE LYON FR (LYON) participant 315˙227.00
10    ETHNIKO KAI KAPODISTRIAKO PANEPISTIMIO ATHINON EL (ATHINA) participant 96˙081.00

Map

 Project objective

“HAP2” aims to develop stratified host-directed drugs and biomarkers to enhance the prevention and the treatment of hospital-acquired pneumonia (HAP) and develop precision medicine in infectious diseases. HAP is an infectious disease of major concern in the world, and the most frequent cause of hospital-acquired infections with 500,000 episodes being treated every year in Europe. Despite the development of European recommendations, the incidence remains high, with dramatic medical consequences: existing therapies and preventive measures do not result in the expected favourable outcome (clinical cure and survival) for 30% of patients. HAP are moreover the main cause of antibiotic consumption in European hospitals and are increasingly induced by drug-resistant pathogens. New, alternative and more effective host-targeted strategies are therefore urgently needed to fight antibiotic resistance. The ambition of “HAP2” is to revolutionize the management of HAP: capitalising on the novel concept of critical-illness related immunosuppression altering the host-pathogens interactions, we propose a complete reappraisal of the physiopathology of HAP based on the concept of respiratory dysbiosis. “The HAP2” project will reach two ground-breaking objectives in the field of bacterial infections: first the development of host-targeted approaches for the prevention and the treatment of a severe bacterial infection through the supplementation of the IL-12/IFN-γ axis which is defective in patients at risk of pneumonia; second the development of a clinico-biological score based on an integrative assessment of the host-pathogen interactions and genetic variation, to predict the course of HAP and the response to treatment. Our interdisciplinary consortium, bringing together 10 partners from academia and industry with expertise in clinical trials, immunology, microbiome analysis, omics and social sciences is uniquely placed to achieve this ambition within this 5-year project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HAP2" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "HAP2" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

DIAdIC (2019)

Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial

Read More